No Data
RBC Capital Maintains Zynex(ZYXI.US) With Buy Rating, Maintains Target Price $11
RBC Capital Sticks to Its Buy Rating for Zynex (ZYXI)
Insider Sale: CHIEF FINANCIAL OFFICER of $ZYXI (ZYXI) Sells 10,000 Shares
Healthcare and Medical Simulation Market Size Expected to Reach USD 7.04 Bn by 2034
An Intrinsic Calculation For Zynex, Inc. (NASDAQ:ZYXI) Suggests It's 22% Undervalued
Pain Management Devices Global Analysis Report 2024-2034 Featuring Abbott Laboratories, Boston Scientific, Medtronic, Nevro, Baxter, OMRON, Stryker, Teleflex, ICU Medical, AtriCure, and Zynex
